ClinicalTrials.gg
Active, not recruitingNCT06391944Updated Apr 30, 2024

JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations

A Phase 2 interventional study of JMT101 Injection and Osimertinib tablet in Local Advanced or Metastatic NSCLC and Harboring EGFR Common Mutation, sponsored by Shanghai JMT-Bio Inc.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-04-30.

Sponsored by Shanghai JMT-Bio Inc. (part of CSPC Pharmaceutical Group Limited) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 5 months after the study started (first participant enrolled Nov 2021, registered Apr 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
161
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Carcinoma, Non-Small-Cell Lung by CSPC Pharmaceutical Group Limited — 11 open to participants now, 12 under way, 7 of them phase 3. Carcinoma, Non-Small-Cell Lung · CSPC Pharmaceutical Group Limited.

Enrollment
12th of 16
161 · median 365
Started
2021
with 1 other
Phase 2
4 of 17
2 open now
Primary completion
2023-05
later than 0 of 11 live
Registered
9th of 17
by date

Among the 17 studies in Carcinoma, Non-Small-Cell Lung by CSPC Pharmaceutical Group Limited, this one is the 12th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2021, is one of 4 in phase 2, reaches primary completion later than 0 of the 11 other live ones, and was the 9th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

11 of the 17 studies in Carcinoma, Non-Small-Cell Lung by CSPC Pharmaceutical Group Limited are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Carcinoma, Non-Small-Cell Lung by CSPC Pharmaceutical Group Limited, or all of them as a file.
02

Study summary

This was a multicenter, open-label phase 2 study. This study aimed to evaluate the efficacy and safety of JMT101 combined with Osimertinib in participants with local advanced or metastatic non-small-cell lung cancer harbouring EGFR common mutation with or without prior systemic therapy.

Efficacy indexes included investigator-assessed Overall Response Rate(ORR), Disease Control Rate(DCR), Duration of Response( DoR), Progression Free Survival (PFS) per RECIST 1.1 and Overall Survival (OS). Safety indexes included Adverse Events incidence and severity. This study included 4 cohorts, cohort 1 included EGFR-mutated advanced NSCLC patients without prior systemic therapy and accepted JMT101 6mg/Kg Q3W and Osimertinib 80mg QD therapy. Cohort 2 included EGFR-mutated advanced NSCLC patients who failed with prior generation 1 or 2 EGFR-TKIs therapy and accepted JMT101 6mg/Kg Q2W and Osimertinib 80mg QD therapy. Cohort 3 included advanced EGFR common mutation NSCLC patients who failed with prior generation 3 EGFR-TKIs but did not accept chemotherapy and accepted JMT101 6mg/Kg Q2W and Osimertinib 80mg or 160mg QD therapy. Cohort 4 included EGFR-mutated advanced EGFR NSCLC patients who failed with prior generation 3 EGFR-TKIs and platinum-based chemotherapy and accepted JMT101 6mg/Kg Q2W and Osimertinib 80mg or 160mg QD therapy.

Read the detailed description

Avoid duplicating information that will be entered elsewhere, such as Eligibility Criteria or Outcome Measures.

03

Conditions studied

  • Local Advanced or Metastatic NSCLC
  • Harboring EGFR Common Mutation
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 18-75 years old.
  2. or cytologically confirmed diagnosis of NSCLC, locally advanced (Stage IIIB and IIIC according to the 8th edition of the AJCC TNM staging criteria) or (Stage IV) harbouring EGFR common mutation with tumour tissue/blood sample. For cohort 1, should not receive prior systemic therapy, for cohort 2, should fail with generation 1 or 2 EGFR-TKIs therapy, for cohort 3, should fail with generation 3 EGFR-TKIs therapy but did not accept chemotherapy, for cohort 4, patients should fail with generation 3 and platinum-based chemotherapy.
  3. At least 1 per Version 1.1.
  4. ≥ 12 weeks.
  5. (ECOG) performance status of 0 to 1.
  6. Adequate organ and hematologic function
  7. Women with fertility tested negative for blood pregnancy within 7 days prior to trial screening; Any male or female patients with fertility must agree to use effective methods throughout the entire trial period and within six months after the end of the trial.
  8. Patients must give to this study before the trial and voluntarily sign a written informed consent form.

Exclusion criteria

Exclusion Criteria:

  1. Previously received EGFR monoclonal antibody therapy.
  2. Have received anti-tumor treatments such as chemotherapy, biological therapy, targeted therapy, immunotherapy, etc. within 4 weeks prior to the first use of the study drug.
  3. Have undergone major organ surgery (excluding ) or experienced significant trauma within 4 weeks prior to the first use of the study drug.
  4. Have received other clinical study drugs within 4 weeks prior to the first use of the study drug.
  5. Known or intolerance to any component of the study drug or its .
  6. Those who use strong or moderate inducers within 14 days before the first administration of the study drug.
  7. The adverse reactions of previous anti-tumor treatments have not yet recovered to 5.0 evaluation ≤ level 1 except for toxicity such as alocepia, which is judged to be of no safety risk by researchers;
  8. Central nervous system or meningeal metastasis with clinical symptoms.
  9. Having a history of diseases, immunodeficiency, including testing positive, or having other acquired or congenital immunodeficiency diseases, or having a history of organ transplantation.
  10. Active (hepatitis B virus titer>1000 copies/mL or 200 IU/mL); virus and syphilis infections.
  11. Have a history of serious cardiovascular disease.
  12. Unable to swallow medication orally, or has a condition that has been determined by researchers to seriously affect gastrointestinal absorption.
  13. Within 5 years prior to the first use of the study drug, there were other malignant tumors, except for localized tumors such as cervical carcinoma in situ, basal cell carcinoma of the skin, and prostate carcinoma in situ that have been confirmed to be cured.
  14. Any evidence of a history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonia requiring treatment, or clinically active interstitial lung disease.
  15. Patients with a history of other serious systemic diseases who have been determined by the researchers to be unsuitable for clinical trials.
  16. Known to have alcohol or drug dependence.
  17. Has a clear history of neurological or psychiatric disorders, including epilepsy or dementia.
  18. Pregnant or lactating women.
  19. The researchers believe that the subjects are not suitable to participate in this clinical study due to other reasons.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
161 participants (actual)

Study arms

  • Experimental
    JMT101 combined with Osimertinib

    JMT101 6mg/kg iv Q2W or Q3W, osimertinib 80mg or 160mg po QD until a treatment discontinuation criterion is met.

    Drug: JMT101 Injection · Drug: Osimertinib tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse events incidence and severity

    Time frame: Up to approximately 60 months after the first participant was enrollment

  2. Overall Response Rate(ORR)per RECST 1.1

    Time frame: Up to approximately 60 months after the first participant was enrollment

Secondary outcomes

  1. Overall Survival (OS)

    Time frame: Up to approximately 60 months after the first participant was enrollment

  2. Progression Free Survival (PFS) per RECIST 1.1

    Time frame: Up to approximately 60 months after the first participant was enrollment

  3. Duration of Response (DoR) per RECST 1.1

    Time frame: Up to approximately 60 months after the first participant was enrollment

  4. Disease Control Rate (DCR) per RECST 1.1

    Time frame: Up to approximately 60 months after the first participant was enrollment

07

Study locations

1 site
  • Li Zhang
    Beijing, Beijing 100036, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in May 2023, 17 months.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 17 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2024
First posted
Apr 30, 2024
StartActual
Nov 21, 2021
Primary completionActual
May 17, 2023
CompletionEst.
Nov 21, 2026
Last update
Apr 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06391944
Responsible party
Sponsor
First posted
Apr 30, 2024
Start date
Nov 21, 2021
Primary completion
May 17, 2023
Completion
Nov 21, 2026 (estimated)
Last update
Apr 30, 2024

Study contacts

Li Zhang, M.D.
principal investigator · Sun Yat-sen University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Becotatug

Start the discussion